Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib, a selective JAK1/JAK2 inhibitor, is the current first line therapy for myelofibrosis (MF), which reduces symptomatology and splenomegaly, but does not clearly modify disease course. 31778911 2020
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV). 31711337 2020
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib (Rux), a Jak1/2 inhibitor, results in reduced spleen size and improvement in constitutional symptoms in the majority of patients with myelofibrosis (MF). 30962501 2020
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Unfortunately, ruxolitinib, the JAK1/2 inhibitor approved by FDA and EMEA for PMF, ameliorates symptoms but does not improve the natural course of the disease, and the cure of PMF is still an unmet clinical need. 31749302 2020
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 AlteredExpression disease BEFREE Only JAK1/2 inhibitor ruxolitinib largely activated ERK1/2 signaling in essential thrombocythemia and PMF (up to 4.6 fold), with a more prominent activation in JAK2V617F positive granulocytes. 30571852 2019
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Seven years after the approval of the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib, it remains the only drug licensed for the treatment of myelofibrosis. 30675650 2019
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib, an orally bioavailable and selective inhibitor of Janus kinase 1 (JAK1) and JAK2, significantly reduces splenomegaly and disease-related symptoms in patients with myelofibrosis (MF). 30997748 2019
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib is the only commercially available JAK1/2 inhibitor approved for the treatment of myelofibrosis-related splenomegaly and symptoms. 31201513 2019
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 AlteredExpression disease BEFREE Pacritinib (PAC), a multi-kinase inhibitor with specificity for JAK2, FLT3, and IRAK1 but sparing JAK1, has demonstrated clinical activity in MF with minimal myelosuppression. 29616317 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 GeneticVariation disease BEFREE We assessed 626 patients with MPN, including 69 with myelofibrosis receiving JAK1/2 inhibitors for lymphoma development. 29907599 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 GeneticVariation disease BEFREE One-hundred Mayo Clinic patients with high/intermediate-risk myelofibrosis (MF) received momelotinib (MMB; JAK1/2 inhibitor) between 2009 and 2010, as part of a phase 1/2 trial (NCT00935987); 73% harbored JAK2 mutations, 16% CALR, 7% MPL, 44% ASXL1, and 18% SRSF2. 29515114 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE In this report, we discuss the clinical history, pathological evaluation, and genomics findings in a patient with JAK2-positive myelofibrosis who developed a secondary myelodysplasia after hematopoietic stem cell transplantation and JAK1/2 inhibitor treatment. 30097215 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012. 30043249 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib, a potent oral JAK1/JAK2 inhibitor remains the only Food and Drug Administration (FDA)-approved medicinal therapy for the treatment of MF. 29480036 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib is a JAK1/2 inhibitor that may control myelofibrosis (MF)-related splenomegaly and symptoms and can be prescribed regardless of age. 30010187 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib is a JAK1/2 inhibitor that is effective in managing symptoms and splenomegaly related to myelofibrosis (MF). 29189896 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Expert commentary: The most mature advances in treatment of myelofibrosis are the development of second-generation JAK1/2 inhibitors and improvements in expanding access to donors for transplantation. 30324817 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Momelotinib is a Janus kinase 1/2 inhibitor in clinical development for the treatment of myelofibrosis. 29283448 2018
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. 27785927 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Of note, ruxolitinib, a JAK1/2 inhibitor approved for the treatment of MF, had no inhibitory activity on this pathway. 28188131 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials. 27740634 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Finally, we review novel therapeutic options for MF including the new JAK1/2 inhibitors, ruxolitinib based combination approaches as well as novel therapeutic agents. 28395559 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib is a dual janus kinase 1 (JAK1)/JAK2 inhibitor used to treat splenomegaly and symptoms associated with myelofibrosis (MF). 28260257 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE The only approved JAK2 inhibitor for myelofibrosis is the dual JAK1 and JAK2 inhibitor, ruxolitinib. 28602585 2017
Entrez Id: 3716
Gene Symbol: JAK1
JAK1
0.100 Biomarker disease BEFREE Ruxolitinib, a JAK1/2 inhibitor, is currently the only drug approved for the treatment of patients with intermediate or high risk MF. 27882812 2017